Survival of Adjuvant Chemotherapy Among Elderly Patients with Stage II Colon Cancer

There have been few previous studies regarding survival and predictive factors for elderly patients with stage II colon cancer who also undergo surgery. This study examined the effects of adjuvant chemotherapy (AC) on long-term survival among elderly patients with stage II colon cancer who underwent...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of gerontology Vol. 12; no. 2; pp. 94 - 99
Main Authors Tsai, Tsung-Chih, Sun, Jia-Ling, Lin, Wen-Li, Lee, Sung-Wei, Chang, Shu-Chan, Wu, Pei-Hua, Huang, Wen-Tsung, Tsao, Chao-Jung
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.06.2018
Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:There have been few previous studies regarding survival and predictive factors for elderly patients with stage II colon cancer who also undergo surgery. This study examined the effects of adjuvant chemotherapy (AC) on long-term survival among elderly patients with stage II colon cancer who underwent surgery. This was a survival analysis study with a retrospective design. We reviewed the records of 98 elderly patients with adenocarcinoma of the colon who underwent a surgical intervention with curative intent from 2006 to 2013 at a teaching hospital in southern Taiwan. Some of those 98 patients also received AC, while others did not. The distant metastasis rates (DM rates), disease-free survival (DFS), deaths as a result of various causes, and overall survival (OS) rates of these two groups were studied. The patients treated with AC did not exhibit better recurrence rates, DM rates, DFS, or OS rates than the patients who did not receive AC (the no-AC patients). In terms of 5-year OS, there was no significant difference between the AC and no-AC patients (p = 0.398). Patients from whom the number of lymph nodes retrieved <12 exhibited significantly poorer OS A significant predictor of poorer DFS was a higher pathologic T stage. Moreover, patients treated with FOLFOX4 had not better outcomes than patients treated with 5-fluorouracil in terms of DFS and OS. Our results indicated no significant difference in OS between elderly patients who received AC and those who did not.
ISSN:1873-9598
DOI:10.1016/j.ijge.2017.11.002